TBXT and chronic myelogenous leukemia, BCR-ABL1 positive: The lung cancer animal model showed 23.18% and 28.2% decrease in the CML content at 1 μM and 3 μM, respectively, in the presence of PFT-HSA-TFT-Cy7.